Oritavancin (Diphosphate) News
Oritavancin (Diphosphate) currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Oritavancin (Diphosphate) with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1)....
- Evidence level: L5
- Predicted indications (20):
- Bacteroidaceae infectious disease (99.5%)
- ophthalmic herpes zoster (99.0%)
- Mycoplasma pneumoniae pneumonia (99.0%)
- skin disease caused by infection (99.0%)
- anaerobic bacteria infectious disease (99.0%)
- orbital cellulitis (99.0%)
- infectious mononucleosis (98.8%)
- tinea corporis (98.6%)
- postinfectious vasculitis (98.4%)
- post-bacterial disorder (98.4%)
- post-infectious syndrome (98.3%)
- acute contagious conjunctivitis (98.2%)
- infective urethral stricture (98.2%)
- otitis externa (98.1%)
- infection-related hemolytic uremic syndrome (98.0%)
- Chagas cardiomyopathy (98.0%)
- furuncular myiasis (97.8%)
- wound myiasis (97.8%)
- creeping myiasis (97.8%)
- myiasis (97.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.